Device Week, 10 May 2019 – Global Arthroscopy Products Market; Biotronik Starts First ICD Study Looking At Sex-Specific Outcomes
Executive Summary
In this edition of Device Week, Medtech Insight's Reed Miller chats with Marion Webb about her upcoming Market Intelligence story covering the global arthroscopy and sports medicine products market, based on Informa's new Meddevicetracker report, with a focus on the fast-growing hip arthroscopy market. And Reed Miller discusses Biotronik's new BIO-LIBRA study designed to measure sex-specific outcomes in patients with non-ischemic cardiomyopathy treated with implantable cardioverter defibrillators (ICD) and cardiac resynchronization defibrillators (CRT-D).
You may also be interested in...
Market Intel: Innovation, Surgical Techniques Drive Arthroscopy, Sports Medicine Products Market
The global market for arthroscopy products and sports medicine devices is expected to reach $9bn by 2023, a CAGR of 4.2%, driven by technological advancements, improved surgical techniques and a growing number of surgeons performing minimally invasive surgeries. With hip fixation devices expected to see double-digit growth by 2023, we'll take a closer look at recent technological innovations driving this sector, the key players, and also offer viewpoints from four orthopedic surgeons on what is driving their decision to adopt technologies. We'll also highlight the latest arthroscopes on the market, which is the fastest-growing segment in the global arthroscopy products market.
Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.
Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.